Past year
All results
- All results
- Verbatim
In the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial data, alirocumab reduced the risk of MACE, defined as death from coronary heart disease, MI, fatal or nonfatal ischemic stroke, or UA requiring hospitalization, by 15% in 18,924 ...
Aug 19, 2024
Jul 3, 2024 · In the overall population in the ODYSSEY OUTCOMES trial, with blinded adjudication of all stroke events, alirocumab significantly reduced the risk of any stroke ...
Apr 20, 2024 · In the overall population in the ODYSSEY OUTCOMES trial, with blinded adjudication of all stroke events, alirocumab significantly reduced the risk of any stroke ...
Sep 6, 2024 · This meta-analysis compares results of mega-trials with results from meta-analyses of smaller trials for the primary outcome and all-cause mortality.
Feb 21, 2024 · This article discusses the results of the FOURIER and ODYSSEY Outcomes trials evaluating the PCSK9 inhibitors evolocumab and alirocumab in secondary ...
Dec 4, 2023 · Alirocumab in patients with polyvascular disease and recent acute coronary syndrome: ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;74:1167–1176. Crossref.
Apr 21, 2024 · Similarly, the use of alirocumab in the ODYSSEY OUTCOMES trial resulted in a 1.6% absolute risk reduction after 2.8 years of follow-up [32].
Jan 13, 2024 · Results of ODYSSEY trial showed that primary event occurred in 9.5 % vs 11.1 % in alirocumab and placebo group respectively suggesting that risk of recurrent ...
May 14, 2024 · In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab was ...
Aug 25, 2024 · Moreover, similarly to evolocumab, alirocumab was associated with reductions in polyvascular disease (coronary, peripheral, and cerebrovascular)-related MACEs ...